218 related articles for article (PubMed ID: 31289919)
1. Targeting KRAS Mutant Lung Cancer Cells with siRNA-Loaded Bovine Serum Albumin Nanoparticles.
Mehta A; Dalle Vedove E; Isert L; Merkel OM
Pharm Res; 2019 Jul; 36(9):133. PubMed ID: 31289919
[TBL] [Abstract][Full Text] [Related]
2. Milk exosomes - Natural nanoparticles for siRNA delivery.
Aqil F; Munagala R; Jeyabalan J; Agrawal AK; Kyakulaga AH; Wilcher SA; Gupta RC
Cancer Lett; 2019 May; 449():186-195. PubMed ID: 30771430
[TBL] [Abstract][Full Text] [Related]
3. Stable and efficient transfection of siRNA for mutated KRAS silencing using novel hybrid nanoparticles.
Lakshmikuttyamma A; Sun Y; Lu B; Undieh AS; Shoyele SA
Mol Pharm; 2014 Dec; 11(12):4415-24. PubMed ID: 25340957
[TBL] [Abstract][Full Text] [Related]
4. A self-assembled polyjuglanin nanoparticle loaded with doxorubicin and anti-Kras siRNA for attenuating multidrug resistance in human lung cancer.
Wen ZM; Jie J; Zhang Y; Liu H; Peng LP
Biochem Biophys Res Commun; 2017 Dec; 493(4):1430-1437. PubMed ID: 28958938
[TBL] [Abstract][Full Text] [Related]
5. Calcium-siRNA Nanocomplexes Optimized by Bovine Serum Albumin Coating Can Achieve Convenient and Efficient siRNA Delivery for Periodontitis Therapy.
Wang Y; Song W; Cui Y; Zhang Y; Mei S; Wang Q
Int J Nanomedicine; 2020; 15():9241-9253. PubMed ID: 33262586
[TBL] [Abstract][Full Text] [Related]
6. Combination therapy with KRAS siRNA and EGFR inhibitor AZD8931 suppresses lung cancer cell growth in vitro.
Zarredar H; Pashapour S; Ansarin K; Khalili M; Baghban R; Farajnia S
J Cell Physiol; 2019 Feb; 234(2):1560-1566. PubMed ID: 30132854
[TBL] [Abstract][Full Text] [Related]
7. Cetuximab-siRNA Conjugate Linked Through Cationized Gelatin Knocks Down KRAS G12C Mutation in NSCLC Sensitizing the Cells Toward Gefitinib.
Sreedurgalakshmi K; Srikar R; Harikrishnan K; Srinivasan L; Rajkumari R
Technol Cancer Res Treat; 2021; 20():15330338211041453. PubMed ID: 34542333
[TBL] [Abstract][Full Text] [Related]
8. Cationic bovine serum albumin based self-assembled nanoparticles as siRNA delivery vector for treating lung metastatic cancer.
Han J; Wang Q; Zhang Z; Gong T; Sun X
Small; 2014 Feb; 10(3):524-35. PubMed ID: 24106138
[TBL] [Abstract][Full Text] [Related]
9. Preparation Optimization of Bovine Serum Albumin Nanoparticles and Its Application for siRNA Delivery.
Wang Y; Chen S; Yang X; Zhang S; Cui C
Drug Des Devel Ther; 2021; 15():1531-1547. PubMed ID: 33883877
[TBL] [Abstract][Full Text] [Related]
10. In vivo activation of PEGylated long circulating lipid nanoparticle to achieve efficient siRNA delivery and target gene knock down in solid tumors.
Sasayama Y; Hasegawa M; Taguchi E; Kubota K; Kuboyama T; Naoi T; Yabuuchi H; Shimai N; Asano M; Tokunaga A; Ishii T; Enokizono J
J Control Release; 2019 Oct; 311-312():245-256. PubMed ID: 31505222
[TBL] [Abstract][Full Text] [Related]
11. Combination of siRNA-directed Kras oncogene silencing and arsenic-induced apoptosis using a nanomedicine strategy for the effective treatment of pancreatic cancer.
Zeng L; Li J; Wang Y; Qian C; Chen Y; Zhang Q; Wu W; Lin Z; Liang J; Shuai X; Huang K
Nanomedicine; 2014 Feb; 10(2):463-72. PubMed ID: 24028894
[TBL] [Abstract][Full Text] [Related]
12. Inhalable siRNA Nanoparticles for Enhanced Tumor-Targeting Treatment of
Zhao G; Ho W; Chu J; Xiong X; Hu B; Boakye-Yiadom KO; Xu X; Zhang XQ
ACS Appl Mater Interfaces; 2023 Jul; 15(26):31273-31284. PubMed ID: 37354089
[No Abstract] [Full Text] [Related]
13. Spermine-Based Poly(β-amino ester)s for siRNA Delivery against Mutated KRAS in Lung Cancer.
Jin Y; Adams F; Isert L; Baldassi D; Merkel OM
Mol Pharm; 2023 Sep; 20(9):4505-4516. PubMed ID: 37578116
[TBL] [Abstract][Full Text] [Related]
14. Intracellular nanoparticle delivery by oncogenic KRAS-mediated macropinocytosis.
Liu X; Ghosh D
Int J Nanomedicine; 2019; 14():6589-6600. PubMed ID: 31496700
[TBL] [Abstract][Full Text] [Related]
15. Targeting the KRAS, p38α, and NF-κB in lung adenocarcinoma cancer cells: The effect of combining RNA interferences with a chemical inhibitor.
Zarredar H; Pashapour S; Farajnia S; Ansarin K; Baradaran B; Ahmadzadeh V; Safari F
J Cell Biochem; 2019 Jun; 120(6):10670-10677. PubMed ID: 30656741
[TBL] [Abstract][Full Text] [Related]
16. Targeted nanodelivery of siRNA against KRAS G12D inhibits pancreatic cancer.
Huang R; Du H; Cheng L; Zhang P; Meng F; Zhong Z
Acta Biomater; 2023 Sep; 168():529-539. PubMed ID: 37451658
[TBL] [Abstract][Full Text] [Related]
17. Antibody-mediated delivery of anti-KRAS-siRNA in vivo overcomes therapy resistance in colon cancer.
Bäumer S; Bäumer N; Appel N; Terheyden L; Fremerey J; Schelhaas S; Wardelmann E; Buchholz F; Berdel WE; Müller-Tidow C
Clin Cancer Res; 2015 Mar; 21(6):1383-94. PubMed ID: 25589625
[TBL] [Abstract][Full Text] [Related]
18. CD44 targeted delivery of siRNA by using HA-decorated nanotechnologies for KRAS silencing in cancer treatment.
Tirella A; Kloc-Muniak K; Good L; Ridden J; Ashford M; Puri S; Tirelli N
Int J Pharm; 2019 Apr; 561():114-123. PubMed ID: 30822503
[TBL] [Abstract][Full Text] [Related]
19. Development of siRNA payloads to target KRAS-mutant cancer.
Yuan TL; Fellmann C; Lee CS; Ritchie CD; Thapar V; Lee LC; Hsu DJ; Grace D; Carver JO; Zuber J; Luo J; McCormick F; Lowe SW
Cancer Discov; 2014 Oct; 4(10):1182-1197. PubMed ID: 25100204
[TBL] [Abstract][Full Text] [Related]
20. IKKβ targeting reduces KRAS-induced lung cancer angiogenesis in vitro and in vivo: A potential anti-angiogenic therapeutic target.
Carneiro-Lobo TC; Scalabrini LC; Magalhães LDS; Cardeal LB; Rodrigues FS; Dos Santos EO; Baldwin AS; Levantini E; Giordano RJ; Bassères DS
Lung Cancer; 2019 Apr; 130():169-178. PubMed ID: 30885340
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
